SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”

MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an inn

Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quart

Fortress Biotech, Inc. (FBIO) Q2 2026 Earnings Call Transcript

NEW YORK, Aug. 7, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investiga

SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”

Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday&#39

Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDA

MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fort

Fortress Biotech is trading below its cash balance, offering deep value relative to its assets and r

Fortress Biotech now holds $256 million in cash and only $39 million in debt, establishing a fortres

SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Jou

MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innov

Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $2.82 per share which beat the analyst

ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Th

Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 mill

Company to host conference call to discuss financial results and provide a corporate update on May 1

MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innov

Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 millio

Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.30) per share which beat the analyst

ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Th

Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium

MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its

Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi ™  generated

HC Wainwright & Co. analyst Joseph Pantginis reiterates Fortress Biotech (NASDAQ:FBIO) with a

Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cypriu

Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $0.11 per share which beat the analyst

Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium

Shares of Fisker Inc. (NYSE: FSR) rose sharply during Friday’s session after the company provided a

Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the comp

Shares of Wynn Resorts, Limited (NASDAQ: WYNN) fell sharply on Friday after the company reported thi

  Tuesday saw 132 companies set new 52-week lows.

  On Tuesday, 99 stocks hit new 52-week lows.

Companies Reporting Before The Bell • LightInTheBox Holding (NYSE:LITB) is estimated to report earn

  On Thursday, 116 companies set new 52-week lows.

  On Wednesday, 258 companies hit new 52-week lows.

  OnFriday, 143 stocks hit new 52-week lows.

  On Friday morning, 446 companies hit new 52-week lows.

  During Monday's session, 101 companies made new 52-week lows.

  On Wednesday, 807 companies reached new 52-week lows.

  During Wednesday's trading, 435 companies set new 52-week lows.

  Wednesday's session saw 784 companies set new 52-week lows.